Europe's Clinical Research Landscape in 2026

The European Union stands at a pivotal moment in clinical research. With the full implementation of the Clinical Trials Regulation (CTR) now complete, the region is seeing steady progress in trial activity while pursuing ambitious reforms to regain global competitiveness. Recent monitoring reports highlight both encouraging trends and areas requiring continued attention, particularly in approval timelines and multinational trial coordination.

Clinical trials form the backbone of medical innovation, allowing researchers to test new treatments, vaccines, and therapies in human volunteers under strict ethical and safety standards. In the EU, these studies cover everything from oncology and rare diseases to advanced therapies involving gene and cell treatments. The current environment reflects years of regulatory evolution aimed at streamlining processes across 27 member states and the broader European Economic Area.

The Clinical Trials Regulation: A New Era of Harmonization

The CTR, formally known as Regulation (EU) No 536/2014, became fully applicable on 31 January 2025. This landmark legislation replaced the previous Clinical Trials Directive and introduced the Clinical Trials Information System (CTIS) as the single portal for submissions, assessments, and public access to information.

Key features include a harmonized assessment procedure involving a reporting member state and concerned member states, stricter timelines, and enhanced transparency. Sponsors must now submit all information through CTIS, enabling better oversight and public scrutiny. The transition of legacy trials from the old system concluded successfully, with thousands of ongoing studies now operating under the new framework.

This shift has created a more unified environment for conducting trials across borders, reducing duplication and improving efficiency for sponsors and ethics committees alike.

Current Statistics and Activity Levels

Monitoring data from the Accelerating Clinical Trials in the EU (ACT EU) initiative provides a clear snapshot of progress. As of early 2026, the CTIS platform has processed approximately 13,000 initial clinical trial applications since its launch, resulting in more than 10,600 authorizations across EU and EEA countries.

Over 6,425 initial clinical trials remain ongoing under the CTR framework. In 2025 alone, around 1,972 new trials were initiated in the EU. These figures demonstrate resilience in the research ecosystem despite global shifts in trial locations.

Public access to trial information has expanded dramatically, with roughly 11,000 trials now searchable on the dedicated EU portal. This level of transparency supports patient recruitment, scientific collaboration, and regulatory accountability.

Leading Countries and Therapeutic Focus Areas

Activity remains concentrated among a few key nations. Spain leads with over 3,450 active trials, followed closely by France (approximately 3,300), Germany (around 2,800), and Italy (about 2,650). These countries benefit from strong healthcare infrastructure, experienced research centers, and effective coordination between national authorities and ethics committees.

Oncology continues to dominate trial portfolios, alongside growing emphasis on rare diseases, advanced therapy medicinal products (ATMPs), and pediatric studies. Immunotherapy, precision medicine, and vaccine development represent high-priority areas, reflecting both public health needs and scientific advances.

Multinational trials, which involve multiple EU countries, show particular promise for accelerating recruitment and generating robust data.

Challenges in Timelines and Implementation

Despite the regulatory overhaul, average approval times in the EU still hover around 100 days for many applications. This compares unfavorably with faster jurisdictions where decisions can occur in 30 to 60 days. Variations in interpretation of the CTR across member states contribute to inconsistencies in validation, ethical review, and conditional approvals.

Non-commercial sponsors, including academic researchers and smaller organizations, sometimes face steeper learning curves with the new digital system. Predictability remains a concern for sponsors planning large-scale or time-sensitive studies.

Addressing these bottlenecks is essential to prevent further erosion of Europe's position in the global clinical research market.

Photo by Collab Media on Unsplash

Impact on Patients and Broader Innovation

Efficient clinical trials directly benefit patients by speeding access to promising new treatments. Europe's patient population stands to gain from improved trial diversity, including greater representation in studies of rare conditions and personalized therapies.

However, a reported decline in Europe's global share of commercial trials has meant fewer opportunities for European patients to participate in cutting-edge research. Estimates suggest tens of thousands of potential trial places have shifted elsewhere over the past decade.

Beyond individual health outcomes, robust trial activity supports job creation in life sciences, strengthens pharmaceutical manufacturing, and reinforces the EU's reputation for high-quality research.

Recent Reports Highlighting Progress and Targets

The ACT EU initiative regularly publishes monitoring reports that track key performance indicators. The latest data covering January to March 2026 shows positive momentum, including additional multinational trial authorizations beyond historical averages.

Longer-term targets include raising the proportion of trials that begin within 200 days to 66 percent by 2030. Early indicators suggest the region is moving in the right direction, with improved coordination helping to meet these goals.

Independent analyses from industry bodies also underscore the importance of sustained investment and policy support to reverse earlier declines in trial starts.

The Proposed Biotech Act and Future Reforms

In December 2025, the European Commission published its proposal for a European Biotech Act. This legislation aims to further modernize the clinical research framework by accelerating authorization timelines, eliminating certain extensions for advanced therapies, and introducing risk-proportionate approaches.

Proposed changes include shortening initial authorization periods to as little as 47 days in straightforward cases and creating regulatory sandboxes for innovative trial designs. These measures seek to make Europe more attractive for biotechnology development while maintaining rigorous safety standards.

Combined with ongoing ACT EU efforts, the Biotech Act represents a strategic push to position the EU as a global leader in health biotechnology.

Stakeholder Perspectives Across the Ecosystem

Regulators emphasize the benefits of harmonization and transparency brought by CTIS. National competent authorities and ethics committees report improved collaboration, though they acknowledge the need for continued training and process refinement.

Pharmaceutical sponsors welcome the single-submission system but stress the importance of consistent application across borders. Academic and non-commercial researchers highlight opportunities for greater cross-border cooperation on investigator-initiated studies.

Patient organizations stress the value of accessible trial information and faster access to innovative treatments, particularly for underserved disease areas.

Actionable Insights for Researchers and Sponsors

Organizations planning trials in Europe should prioritize early engagement with the CTIS platform and familiarization with updated guidance. Leveraging the reporting member state mechanism can streamline multinational applications.

Building strong relationships with national authorities and ethics committees helps navigate any remaining variations in interpretation. Monitoring ACT EU reports provides valuable benchmarks for planning and performance evaluation.

Investing in decentralized or hybrid trial models, supported by digital tools, can further enhance recruitment and retention while aligning with emerging regulatory expectations.

Photo by François Genon on Unsplash

Looking Ahead: Sustaining Momentum Through 2030

The full rollout of the CTR and the momentum behind the Biotech Act proposal signal a renewed commitment to clinical research excellence in Europe. With targeted improvements in timelines, coordination, and innovation support, the region is well-positioned to increase its share of global trials.

Success will depend on collaborative efforts among regulators, sponsors, researchers, and patient groups. Continued monitoring and adaptive policy-making will ensure that Europe remains a preferred destination for high-quality, ethical clinical research that ultimately improves health outcomes worldwide.

Stakeholders across the continent are encouraged to engage with available resources and contribute to ongoing refinement of the regulatory environment.